CJ-13,610 hydrochloride is a potent, orally active non-redox 5-lipoxygenase inhibitor with an IC50 value of 0.07 μM. It competes with high affinity at a regulatory LOOH-binding site on activated 5-lipoxygenase, thereby preventing its catalytic activity. It shows potential for investigating diseases associated with elevated 5-lipoxygenase levels, such as inflammatory responses, allergic asthma, various types of cancer, and atherosclerosis.